Celgene has announced a four-year strategic research collaboration with Vividion Therapeutics to utilise its platform, which allows protein-drug interactions to be measured directly within native biological systems, to identify new targets for a range of oncology, inflammatory and neurodegenerative disease. The deal is one of many Celgene has made so far in 2018, including the substantial acquisitions of Juno Therapeutics and Impact Biomedicines.